 Fibroblast Growth Factor 2
"Fibroblast Growth Factor 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A single-chain polypeptide growth factor that plays a significant role in the process of WOUND HEALING and is a potent inducer of PHYSIOLOGIC ANGIOGENESIS. Several different forms of the human protein exist ranging from 18-24 kDa in size due to the use of alternative start sites within the fgf-2 gene. It has a 55 percent amino acid residue identity to FIBROBLAST GROWTH FACTOR 1 and has potent heparin-binding activity. The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages. It was originally named basic fibroblast growth factor based upon its chemical properties and to distinguish it from acidic fibroblast growth factor (FIBROBLAST GROWTH FACTOR 1).
| Descriptor ID |
D016222
|
| MeSH Number(s) |
D12.644.276.624.120 D12.776.467.624.120 D23.529.624.120
|
| Concept/Terms |
Fibroblast Growth Factor 2- Fibroblast Growth Factor 2
- Basic Fibroblast Growth Factor
- Class II Heparin-Binding Growth Factor
- Heparin-Binding Growth Factor Class II
- HBGF-2
- Prostatropin
- FGF-2
- FGF 2
- FGF2
- Fibroblast Growth Factor, Basic
- Fibroblast Growth Factor-2
- Cartilage-Derived Growth Factor
- Cartilage Derived Growth Factor
- Prostate Epithelial Cell Growth Factor
|
Below are MeSH descriptors whose meaning is more general than "Fibroblast Growth Factor 2".
Below are MeSH descriptors whose meaning is more specific than "Fibroblast Growth Factor 2".
This graph shows the total number of publications written about "Fibroblast Growth Factor 2" by people in this website by year, and whether "Fibroblast Growth Factor 2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 3 | 0 | 3 | | 1994 | 0 | 2 | 2 | | 1995 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 3 | 0 | 3 | | 1998 | 1 | 1 | 2 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2002 | 1 | 2 | 3 | | 2003 | 1 | 2 | 3 | | 2004 | 1 | 3 | 4 | | 2005 | 1 | 1 | 2 | | 2006 | 6 | 2 | 8 | | 2007 | 4 | 2 | 6 | | 2008 | 1 | 4 | 5 | | 2009 | 2 | 1 | 3 | | 2010 | 2 | 2 | 4 | | 2011 | 0 | 2 | 2 | | 2012 | 0 | 1 | 1 | | 2013 | 0 | 3 | 3 | | 2014 | 0 | 1 | 1 | | 2015 | 1 | 0 | 1 | | 2016 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 | | 2022 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Fibroblast Growth Factor 2" by people in Profiles.
-
Parsegian K. The BMP and FGF pathways reciprocally regulate odontoblast differentiation. Connect Tissue Res. 2023 01; 64(1):53-63.
-
Parsegian K. The inhibition of mineralisation by fibroblast growth factor 2 is associated with the altered expression of genes regulating phosphate balance. Aust Endod J. 2023 Aug; 49(2):324-331.
-
Giulianelli S, Riggio M, Guillardoy T, P?rez Pi?ero C, Gorostiaga MA, Sequeira G, Pataccini G, Abascal MF, Toledo MF, Jacobsen BM, Guerreiro AC, Barros A, Novaro V, Monteiro FL, Amado F, Gass H, Abba M, Helguero LA, Lanari C. FGF2 induces breast cancer growth through ligand-independent activation and recruitment of ERa and PRB?4 isoform to MYC regulatory sequences. Int J Cancer. 2019 10 01; 145(7):1874-1888.
-
Sahores A, Figueroa V, May M, Liguori M, Rubstein A, Fuentes C, Jacobsen BM, El?a A, Rojas P, Sequeira GR, ?lvarez MM, Gonz?lez P, Gass H, Hewitt S, Molinolo A, Lanari C, Lamb CA. Increased High Molecular Weight FGF2 in Endocrine-Resistant Breast Cancer. Horm Cancer. 2018 10; 9(5):338-348.
-
Yang Y, Haeger SM, Suflita MA, Zhang F, Dailey KL, Colbert JF, Ford JA, Picon MA, Stearman RS, Lin L, Liu X, Han X, Linhardt RJ, Schmidt EP. Fibroblast Growth Factor Signaling Mediates Pulmonary Endothelial Glycocalyx Reconstitution. Am J Respir Cell Mol Biol. 2017 06; 56(6):727-737.
-
Nakachi I, Helfrich BA, Spillman MA, Mickler EA, Olson CJ, Rice JL, Coldren CD, Heasley LE, Geraci MW, Stearman RS. PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines. Clin Transl Sci. 2016 12; 9(6):293-301.
-
Giannotti G, Caffino L, Mottarlini F, Racagni G, Fumagalli F. Region-specific effects of developmental exposure to cocaine on fibroblast growth factor-2 expression in the rat brain. Psychopharmacology (Berl). 2016 Jul; 233(14):2699-704.
-
Wang ZG, Cheng Y, Yu XC, Ye LB, Xia QH, Johnson NR, Wei X, Chen DQ, Cao G, Fu XB, Li XK, Zhang HY, Xiao J. bFGF Protects Against Blood-Brain Barrier Damage Through Junction Protein Regulation via PI3K-Akt-Rac1 Pathway Following Traumatic Brain Injury. Mol Neurobiol. 2016 12; 53(10):7298-7311.
-
Giannotti G, Caffino L, Malpighi C, Melfi S, Racagni G, Fumagalli F. A single exposure to cocaine during development elicits regionally-selective changes in basal basic Fibroblast Growth Factor (FGF-2) gene expression and alters the trophic response to a second injection. Psychopharmacology (Berl). 2015 Feb; 232(4):713-9.
-
Marek LA, Hinz TK, von M?ssenhausen A, Olszewski KA, Kleczko EK, Boehm D, Weiser-Evans MC, Nemenoff RA, Hoffmann H, Warth A, Gozgit JM, Perner S, Heasley LE. Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma. Mol Cancer Res. 2014 Oct; 12(10):1460-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|